Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
The Prognosis For Puma Biotechnology (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Executives Under Investigation for Breast Cancer Drug — Schubert Jonckheer & Kolbe
Puma Biotechnology
Alan H. Auerbach - Los Angeles Business Journal
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology
Puma Biotechnology Inc
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology
Puma Biotechnology Reports Third Quarter 2022 Financial Results | Business Wire
Puma Biotechnology
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Puma shares nearly triple on drug news, but options smell 'fishy'
Conspiracy Theory: Did Puma Biotech Exec Resign Because of Bad News Ahead? | BioSpace
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotechnology, Inc.
Goldman Sachs Group Cuts Stake in Puma Biotechnology (PBYI)
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ https://t.co/LR02TGd4oT" / Twitter
